Savara (NASDAQ:SVRA) Hits New 52-Week Low After Analyst Downgrade

Savara Inc (NASDAQ:SVRA) shares hit a new 52-week low during mid-day trading on Thursday after HC Wainwright lowered their price target on the stock from $10.00 to $6.00. HC Wainwright currently has a buy rating on the stock. Savara traded as low as $3.24 and last traded at $3.32, with a volume of 128515 shares changing hands. The stock had previously closed at $3.25.

Several other brokerages have also weighed in on SVRA. Evercore ISI reaffirmed an “in-line” rating and set a $5.00 target price (down previously from $7.00) on shares of Savara in a research note on Wednesday. JMP Securities reaffirmed a “market outperform” rating and set a $9.00 target price on shares of Savara in a research note on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $10.17.

Institutional Trading of Savara

Several hedge funds have recently made changes to their positions in the business. ProShare Advisors LLC lifted its position in shares of Savara by 9.0% during the first quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock worth $128,000 after purchasing an additional 2,114 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Savara by 9.0% during the third quarter. The Manufacturers Life Insurance Company now owns 44,956 shares of the company’s stock worth $191,000 after purchasing an additional 3,706 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Savara by 15.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 33,692 shares of the company’s stock worth $168,000 after purchasing an additional 4,625 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Savara by 14.9% during the second quarter. The Manufacturers Life Insurance Company now owns 41,250 shares of the company’s stock worth $166,000 after purchasing an additional 5,335 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Savara by 5.1% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,815 shares of the company’s stock worth $533,000 after purchasing an additional 6,141 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Price Performance

The firm has a market cap of $525.08 million, a price-to-earnings ratio of -7.60 and a beta of 1.02. The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26. The company’s 50-day moving average price is $3.93 and its 200-day moving average price is $4.21.

Savara (NASDAQ:SVRA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11). On average, equities research analysts forecast that Savara Inc will post -0.44 EPS for the current year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.